<DOC>
	<DOCNO>NCT00261482</DOCNO>
	<brief_summary>The purpose study evaluate user experience EVRAÂ® Contraceptive Transdermal Patch ; specifically , user satisfaction EVRAÂ® Patch , applicable , user preference EVRAÂ® Patch compare previous method contraception . The study also evaluate contraceptive efficacy , safety user compliance .</brief_summary>
	<brief_title>Evaluation Women 's Experience With EVRA ( Norelgestromin + Ethinyl Estradiol ) Transdermal Contraceptive Patch Compared With Previous Methods Contraception .</brief_title>
	<detailed_description>EVRA first transdermal contraceptive patch receive approval Health Canada Marketing Authorization throughout European Union . This open-label , single-arm , multicenter clinical study treatment duration 24 week ( 6 treatment cycle 4 week ) . Four clinic visit schedule : screen Visit 1 , subject ask complete set question satisfaction current method contraception , question overall health status . Visits 2 , 3 , 4 follow Cycles 1 , 3 , 6 , respectively EVRA treatment . At Visits 3 4 , subject ask answer question satisfaction EVRA , overall health status . At Visit 4 ( final study visit ) subject ask compare EVRA previously use contraceptive method . Compliance assess visit return box study medication review Diary Cards subject record date site patch application , detail patch detachment . The study generate first large-scale , European dataset woman 's experience EVRA , include satisfaction , safety , efficacy , compliance . These data compare subject ' experience previously use method contraception . Each EVRA patch , contain 6 mg NGMN 600 ug EE , deliver 150 microgram NGMN 20 ug EE 24 hour 7 day , worn 1 week replace 3 consecutive week . The fourth week patch-free . Subjects wear EVRA 1 4 area : buttock , abdomen , upper torso , upper arm .</detailed_description>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Regular menstrual cycle sexually active risk pregnancy nonpregnant normal Pap smear Presently risk venous thrombosis arterial thrombosis migraine focal aura severe hypertension diabetes mellitus hereditary dyslipoproteinemia carcinoma breast , endometrium estrogendependent neoplasia substance abuse skin condition concurrent use hormonecontaining medication smoke woman 35 year age .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>contraception</keyword>
	<keyword>female contraception</keyword>
	<keyword>hormonal contraception</keyword>
	<keyword>transdermal contraception</keyword>
	<keyword>EVRA</keyword>
	<keyword>estrogen</keyword>
	<keyword>progestin</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>norelgestromin</keyword>
</DOC>